https://www.selleckchem.com/pr....oducts/ulixertinib-b
7% (n = 5) developed bradycardia. Age, initial heart rate, time between CCB and BB administration, addition of an oral CCB or BB administration, or administration of IV magnesium did not impact target heart rate achievement. Conclusion Adding a second nodal blocker in patients who did not achieve rate control with the first agent resulted in heart rate control 46% of the time. The development of symptomatic bradycardia was uncommon.Background Tocilizumab, a humanized monoclonal antibody, targets IL-6 receptors bloc
Like
Comment
Share
